Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1981 Aug;12(2):229–233. doi: 10.1111/j.1365-2125.1981.tb01205.x

The combination of nifedipine and propranolol in the management of patients with angina pectoris.

A C Tweddel, J M Beattie, R G Murray, I Hutton
PMCID: PMC1401877  PMID: 7030373

Abstract

1 A double-blind cross over study was carried out to assess the effects of the combination of nifedipine and propranolol in 25 patients with chronic stable angina pectoris at beta-adrenoceptor blockade. 2 Efficacy was judged objectively by a standardized exercise protocol using a bicycle ergometer and subjectively by patient assessment of anginal attack rate. 3 The combination of nifedipine and propranolol was shown to be effective with an increase in exercise time to angina and an increase in physical work capacity expressed in terms of calculated maximal oxygen uptake (VO2 max). There was an associated reduction in anginal attack rate. 4 The synergistic effect was even more pronounced after reduction in propranolol dosage to 50% of the beta-adrenoceptor blocking dose, reflecting the myocardial depressant effects of beta-adrenoceptor blocking drugs in these patients with coronary heart disease, some of whom had poor left ventricular function.

Full text

PDF
229

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amsterdam E. A., Gorlin R., Wolfson S. Evaluation of long-term use of propranolol in angina pectoris. JAMA. 1969 Oct 6;210(1):103–106. [PubMed] [Google Scholar]
  2. Atterhög J. H., Ekelund L. G., Melin A. L. Effect of nifedipine on exercise tolerance in patients with angina pectoris. Eur J Clin Pharmacol. 1975 Feb 28;8(2):125–130. doi: 10.1007/BF00561561. [DOI] [PubMed] [Google Scholar]
  3. Blomqvist C. G. Exercise testing in rheumatic heart disease. Cardiovasc Clin. 1973;5(2):267–287. [PubMed] [Google Scholar]
  4. Braunwald E. Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol. 1971 Apr;27(4):416–432. doi: 10.1016/0002-9149(71)90439-5. [DOI] [PubMed] [Google Scholar]
  5. Coltart D. J., Shand D. G. Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man. Br Med J. 1970 Sep 26;3(5725):731–734. doi: 10.1136/bmj.3.5725.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Crawford M. H., LeWinter M. M., O'Rourke R. A., Karliner J. S., Ross J., Jr Combined propranolol and digoxin therapy in angina pectoris. Ann Intern Med. 1975 Oct;83(4):449–455. doi: 10.7326/0003-4819-83-4-449. [DOI] [PubMed] [Google Scholar]
  7. Ekelund L. G., Orö L. Antianginal efficiency of nifedipine with and without a beta-blocker, studied with exercise test. A double-blind, randomized subacute study. Clin Cardiol. 1979 Jun;2(3):203–211. doi: 10.1002/clc.4960020306. [DOI] [PubMed] [Google Scholar]
  8. Fox K. M., Selwyn A. P., Shillingford J. P. A method for praecordial surface mapping of the exercise electrocardiogram. Br Heart J. 1978 Dec;40(12):1339–1343. doi: 10.1136/hrt.40.12.1339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Greenblatt D. J., Koch-Weser J. Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program. Drugs. 1974;7(1):118–129. doi: 10.2165/00003495-197407010-00008. [DOI] [PubMed] [Google Scholar]
  10. Hancock E. W., Eldridge F. Muscular subaortic stenosis. Reversibility with varying cardiac cycle length. Am J Cardiol. 1966 Oct;18(4):515–521. doi: 10.1016/0002-9149(66)90003-8. [DOI] [PubMed] [Google Scholar]
  11. Heupler F. A., Jr, Proudfit W. L. Nifedipine therapy for refractory coronary arterial spasm. Am J Cardiol. 1979 Oct 22;44(5):798–803. doi: 10.1016/0002-9149(79)90200-5. [DOI] [PubMed] [Google Scholar]
  12. Klugmann S., Salvi A., Camerini F. Haemodynamic effects of nifedipine in heart failure. Br Heart J. 1980 Apr;43(4):440–446. doi: 10.1136/hrt.43.4.440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mitchell J. H., Blomqvist G. Maximal oxygen uptake. N Engl J Med. 1971 May 6;284(18):1018–1022. doi: 10.1056/NEJM197105062841809. [DOI] [PubMed] [Google Scholar]
  14. Oakley G. D., Fox K. M., Dargie H. J., Selwyn A. P. Objective assessment of treatment in severe angina. Br Med J. 1979 Jun 9;1(6177):1540–1540. doi: 10.1136/bmj.1.6177.1540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Olivari M. T., Bartorelli C., Polese A., Fiorentini C., Moruzzi P., Guazzi M. D. Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation. 1979 May;59(5):1056–1062. doi: 10.1161/01.cir.59.5.1056. [DOI] [PubMed] [Google Scholar]
  16. Opie L. H. Drugs and the heart. Lancet. 1980 Mar 29;1(8170):693–698. [PubMed] [Google Scholar]
  17. de Ponti C., Mauri F., Ciliberto G. R., Carù B. Comparative effects of nifedipine, verapamil, isosorbide dinitrate and propranolol on exercise-induced angina pectoris. Eur J Cardiol. 1979 Jul;10(1):47–58. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES